Skip to main content
Terug
BOEUF logo

Bonesupport Holding AB (publ)

Datakwaliteit: 100%
BOEUF
OTC Healthcare Medical - Instruments & Supplies
€ 21,00
€ 0,00 (0,00%)
Marktkapitalisatie: 1,38B
Dagbereik
€ 19,00 € 21,00
52-Weeksbereik
€ 18,57 € 35,00
Volume
760
50D / 200D Gem.
€ 20,95 / € 25,69
Vorige Slotkoers
€ 21,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 9,8 0,4
P/B 1,6 2,9
ROE % 17,8 3,7
Net Margin % 12,1 3,8
Rev Growth 5Y % 53,2 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 53,17% annually over 5 years — strong growth
ROE of 17,81% — decent returns on equity
Debt/Equity of 0,01 — conservative balance sheet
Generating 218,19M in free cash flow
P/E of 9,75 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 22,80%

Groei

Revenue Growth (5Y)
53,17%
Revenue (1Y)30,37%
Earnings (1Y)6,01%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
17,81%
ROIC23,61%
Net Margin12,10%
Op. Margin23,55%

Veiligheid

Debt / Equity
0,01
Current Ratio4,85
Interest Coverage8,60

Waardering

P/E Ratio
9,75
P/B Ratio1,60
EV/EBITDA3,69
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 30,37% Revenue Growth (3Y) 40,80%
Earnings Growth (1Y) 6,01% Earnings Growth (3Y) -23,93%
Revenue Growth (5Y) 53,17% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,17B Net Income (TTM) 141,80M
ROE 17,81% ROA 13,72%
Gross Margin 92,57% Operating Margin 23,55%
Net Margin 12,10% Free Cash Flow (TTM) 218,19M
ROIC 23,61% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 4,85
Interest Coverage 8,60 Dividend Yield 0,00%
Valuation
P/E Ratio 9,75 P/B Ratio 1,60
P/S Ratio 1,18 PEG Ratio 21,62
EV/EBITDA 3,69 Dividend Yield 0,00%
Market Cap 1,38B Enterprise Value 1,02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,17B 898,73M 591,08M 328,82M 212,89M
Net Income 141,80M 133,75M 245,02M -68,17M -85,53M
EPS (Diluted) 2,12 2,01 3,74 -1,06 -1,34
Gross Profit 1,08B 832,25M 540,92M 297,71M 189,70M
Operating Income 275,98M 166,15M 13,93M -64,54M -80,67M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,03B 879,69M 688,82M 371,82M 343,92M
Total Liabilities 168,46M 152,23M 143,64M 102,89M 78,22M
Shareholders' Equity 865,08M 727,46M 545,18M 268,93M 265,70M
Total Debt 11,68M 14,59M 17,48M 17,45M 21,42M
Cash & Equivalents 377,04M 227,00M 166,93M 201,28M 206,46M
Current Assets 794,66M 622,60M 402,94M 338,81M 308,48M
Current Liabilities 163,91M 144,19M 130,06M 90,20M 61,70M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#477 of 1024
46
Custom Contrarian Investing (David Dreman)
#391 of 658
22

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026